Results 111 to 120 of about 518,936 (262)

Dynamic antigen expression and cytotoxic T cell resistance in HIV reservoir clones. [PDF]

Nature
Ferreira IATM, Herrera A, Huynh TT, Stone E, Linden NL, Ovies C, Ren Y, Bittar C, Pal VK, Naing E, Sinha P, Danesh A, Stevenson E, Vedova S, Liu F, Leyre L, Shea S, Wells E, Miller IG, Canis M, Teixeira AR, Moir S, Chun TW, Kovacs C, Gastonguay MS, Hill AL, Genel S, Zumbo P, Betel D, Halvas EK, Lee GQ, Scheck R, Caskey M, Bieniasz PD, Board NL, Nussenzweig MC, Jones RB.   +36 more
europepmc   +1 more source

Chronobiology of Cancer: How Aging Fuels Oncogenesis at the Molecular Level

Aging and Cancer, EarlyView.
This graphical abstract illustrates the key biological pathways linking aging with cancer development and progression. In the upper left, cumulative exposure to ultraviolet radiation, toxins, and reactive oxygen species (ROS) causes DNA damage and genomic instability, whereas age‐related decline in repair mechanisms, such as ATM/ATR, BER, and NER ...
Anu Singh, Aroonima Misra, Sufian Zaheer
wiley   +1 more source

The challenge of cytotoxic T cell responses in carcinoma with a focus on lung carcinoma. [PDF]

Front Oncol
Dash A, Banisadr A, Al Dikka D, Johns SC, Fuster MM.   +4 more
europepmc   +1 more source

Super‐Refractory Status Epilepticus (SRSE) in a Patient With Compound Heterozygous OPA1 Variants: Case Report and Literature Review

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Super‐Refractory Status Epilepticus (SRSE) is a rare, life‐threatening neurological emergency with unclear etiology in many cases. Mitochondrial dysfunction, often due to disease‐causing genetic variants, is increasingly recognized as a cause, with each gene producing distinct pathophysiological mechanisms.
Pouria Mohammadi, Lara Basovic, Christopher Michael McGraw   +2 more
wiley   +1 more source

Ofatumumab in Myelin Oligodendrocyte Glycoprotein Antibody–Associated Disease: A Comparison With Rituximab

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective To evaluate the efficacy and safety of ofatumumab in patients with myelin oligodendrocyte glycoprotein antibody–associated disease (MOGAD), and compare it with rituximab. Methods We conducted a single–center, observational study including 22 MOGAD patients treated with ofatumumab and 21 treated with rituximab.
Yuxin Fan, Lei Zhou, Jingzi ZhangBao, Hongmei Tan, Zhouzhou Wang, Chao Quan   +5 more
wiley   +1 more source

Cytotoxic T-cell deficiency and sustained B-cell activation in serofast syphilis: a prospective observational study. [PDF]

Front Immunol
Kaminiów K, Kiołbasa M, Napiórkowska-Baran K, Pastuszczak M.   +3 more
europepmc   +1 more source

Anti‐CD19 CAR T Cells in Autoimmune Encephalitis: Inflammation Controlled, Neurodegeneration Unchecked?

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Just recently, successful chimeric antigen receptor (CAR) T cell therapy was reported in the first patient with refractory, anti‐diacylglycerol lipase alpha (DAGLA) antibody‐mediated autoimmune encephalitis, achieving partial clinical remission.
Dimitrios Mougiakakos, Marwa Al‐Dubai, Denise Walther, Dominic Borie, Jan D. Lünemann, Marc Pawlitzki, Sven G. Meuth, Solveig Henneicke, Stefan Vielhaber, Stefanie Schreiber   +9 more
wiley   +1 more source

Single-cell transcriptomic profiling reveals CD27⁺ cytotoxic T Cell heterogeneity and exhaustion dynamics in colorectal cancer tumor microenvironment. [PDF]

Front Genet
Xu W, Huang H, Mao L, Zhu H, Feng Z.
europepmc   +1 more source

Refined single-cell profiling captures a CCR5^high CD4⁺ cytotoxic T-cell precursor in multiple sclerosis. [PDF]

EBioMedicine
van Puijfelik F, Rip J, van Hasselt Y, Wierenga-Wolf AF, Shyfrin S, Pelser AC, Melief MJ, Klein Kranenbarg RAM, Bindels EM, van de Werken HJG, van Ansenwoude CMJ, de Vries HE, Dik WA, de Beukelaar J, Smets I, Wokke BH, Smolders J, van Luijn MM.   +17 more
europepmc   +1 more source

Disease Course After Anti‐CD20 Discontinuation in Secondary Progressive Multiple Sclerosis—A Multicenter Long‐Term Longitudinal Study

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective To describe long‐term outcomes after anti‐CD20 discontinuation in selected patients with secondary progressive multiple sclerosis (SPMS) who remained without subsequent disease‐modifying therapy (DMT). Methods We retrospectively analyzed data from four centers in Austria and Switzerland.
Ferdinand Otto, Dariia Kliushnikova, Richard Friedrich Radlberger, Sinan Yasaroglu, Tobias Moser, Andrea Harrer, Kitty Kratzer, Wolfgang Hitzl, Christiane Gradl, Martin Schmidauer, Patrick Roth, Harald Hegen, Peter Wipfler   +12 more
wiley   +1 more source